Key result
VERTIS CV post-hoc study evaluates ertugliflozin versus placebo on kidney outcomes after cardiovascular events.
Why the study?
Little is known about the trajectory of kidney function change after a cardiovascular event, especially in people treated with SGLT2 inhibitors such as ertugliflozin.
Does ertugliflozin alter the association between interval cardiovascular events and kidney outcomes compared to placebo?
RCT
Does ertugliflozin alter the association between interval cardiovascular events and kidney outcomes compared to placebo?
Answers are grounded in this paper and cite their sources.
Cardiovascular (CV) events are associated with an increased risk of kidney disease progression.1 However, little is known about the trajectory of kidney function change after a CV event, particularly in people treated with contemporary kidney-protective medications such as sodium–glucose cotransporter 2 (SGLT2) inhibitors. We performed a post-hoc analysis using data from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular< outcomes trial (VERTIS CV; protocol MK-8835-004; ClinicalTrials.gov: NCT01986881) to assess if the association between interval CV events (ICVEs) and kidney outcomes differed between the ertugliflozin and placebo groups.
No takes yet. Share an insight, caveat, or question.
Odutayo et al. (2026) conducted an RCT in Cardiovascular events and kidney disease. Ertugliflozin vs. Placebo was evaluated on Kidney outcomes after interval cardiovascular events. The abstract outlines a post-hoc analysis of the VERTIS CV trial assessing the effect of ertugliflozin versus placebo on kidney outcomes after interval cardiovascular events, but reports no results.
Synapse has enriched 10 related papers. Consider them for comparative context: